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Abstract
ProleukinR Observational Study to Evaluate the Treatment Patterns and Clinical Response in 
Malignancy (PROCLAIMSM) is the largest observational clinical database of high-dose 
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interleukin-2 (HD IL-2)-treated patients in the US. Herein, the survival and outcome for patients 
with renal cell carcinoma receiving HD IL-2 in sequence with targeted therapy are described. HD 
IL-2 has an acceptable efficacy and safety profile in current clinical practice and remains a 
valuable therapy for patients with renal cell carcinoma.
Background: This analysis describes the outcome for patients who received targeted therapy 
(TT) prior to or following high-dose interleukin-2 (HD IL-2).
Patients and Methods: Patients with renal cell carcinoma (n = 352) receiving HD IL-2 were 
enrolled in ProleukinR Observational Study to Evaluate the Treatment Patterns and Clinical 
Response in Malignancy (PROCLAIMSM) beginning in 2011. Statistical analyses were performed 
using datasets as of September 24, 2015.
Results: Overall, there were 4% complete response (CR), 13% partial response (PR), 39% stable 
disease (SD), and 43% progressive disease (PD) with HD IL-2. The median overall survival 
(mOS) was not reached in patients with CR, PR, or SD, and was 15.5 months in patients with PD 
(median follow-up, 21 months). Sixty-one patients had prior TT before HD IL-2 with an overall 
response rate (ORR) to HD IL-2 of 19% (1 CR, 9 PR) and an mOS of 22.1 months. One hundred 
forty-nine patients received TT only after HD IL-2 with an mOS of 35.5 months. One hundred 
forty-two patients had no TT before or after HD IL-2, and mOS was not reached. The mOS was 
8.5 months in PD patients who received HD IL-2 without follow-on TT and 29.7 months in PD 
patients who received follow-on TT after HD IL-2.
Conclusions: HD IL-2 as sole front-line therapy, in the absence of added TT, shows extended 
clinical benefit (CR, PR, and SD). Patients with PD after HD IL-2 appear to benefit from follow-
on TT. Patients who progressed on TT and received follow-on HD IL-2 experienced major clinical 
benefit. HD IL-2 therapy should be considered in eligible patients.
Keywords
Anti-VEGF therapy; Cytokine; Kidney cancer; Therapy trends; Toxicity
Introduction
Nearly 64,000 new cases of renal cell carcinoma (RCC) were diagnosed and over 13,000 
deaths occurred in the United States in 2014.1 Although surgical resection of localized RCC 
can be curative, 20% to 40% of patients with RCC develop metastases after primary 
nephrectomy.2 Prior to the advent of targeted therapy, metastatic RCC (mRCC) had an 
historical 5-year survival rate of 5% to 10% and median overall survival (mOS) of 13 
months.3 The US Food and Drug Administration approval of novel targeted therapies (TT), 
including inhibitors of the vascular endothelial growth factor (VEGF) pathway (axitinib, 
bevacizumab, pazopanib, sorafenib, sunitinib) and inhibitors of the mammalian target of 
rapamycin (mTOR) pathway (temsirolimus and everolimus),4–7 in the past decade has led to 
prolongation of mOS to about 28 months in 2012.6 More recent approval of cabozantinib 
(2016), nivolumab (2015), and the combination of lenvatinib with everolimus (2016) have 
added to the treatment landscape of mRCC for second-line.8–10 Despite the success of TT, 
the optimal management of mRCC remains a therapeutic challenge as complete durable 
responses are rare, and alternative therapy options often need to be considered.
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Prior to the availability and adoption of TTs, immunotherapy with high-dose interleukin-2 
(HD IL-2) was a well-established therapeutic approach to mRCC.11 The safety and efficacy 
data that led to the approval of HD IL-2 in 1992 was based on 255 treated patients derived 
from a pool of 7 nonrandomized phase II clinical trials.12,13 These earlier studies revealed 
the overall response rate (ORR) to be 15% with an mOS of 16.3 months, and the treatment-
related death rate to be 4%.2 Recent data for the use of HD IL-2 in mRCC shows an 
improved profile of overall safety and efficacy. In a study of 88 patients diagnosed with 
mRCC treated at Roswell Park between 2004 and 2011, the observed mOS was 35.5 
months.14 A retrospective analysis performed at Providence Portland Cancer Center 
involving 186 patients with mRCC treated with HD IL-2 revealed an ORR of 24% and a 3-
year survival rate of 44%, and the reported IL-2-related death rate among 500 treated 
patients was less than 1%.15 A prospective multicenter Cytokine Working Group study of 
120 patients with mRCC treated between 2006 and 2009, reported an ORR of 25% and an 
mOS of 42.8 months.16 Taken together, these reports of patients treated with HD IL-2 during 
2004 to 2011, perhaps with improved patient selection, but also clearly in the era of TT, 
suggest longer survival for patients receiving HD IL-2 than in the earlier HD IL-2 reports.
14–16
This has led us to evaluate the outcome of HD IL-2 treatment in patients who may have had 
sequential therapies for metastatic RCC. ProleukinR Observational Study to Evaluate the 
Treatment Patterns and Clinical Response in Malignancy (PROCLAIMSM) registry 
(NCT01415167), a national observational database, was established in 2011 to document 
and study the current treatment outcomes with HD IL-2.17 The registry is designed to create 
a clinical database of patients diagnosed with mRCC or metastatic melanoma who are 
treated with HD IL-2 alone or HD IL-2 in combination or sequence with other therapies. At 
the time of this report, there are 44 sites participating in the PROCLAIMSM registry, with over 
1300 patients enrolled to date. Follow-up data at the time of this analysis are available for 
1280 patients, including both retrospectively and prospectively collected data 
(www.proclaimregistry.com). In the prospectively enrolled cohort, there are currently 385 
patients with melanoma and 496 patients with mRCC with confirmed disease classification. 
Herein, we report the survival outcome of patients with mRCC treated with HD IL-2 within 
the TT era based on findings from patients enrolled prospectively in the PROCLAIMSM 
database (2011 to 2014). This consists of 352 patients with follow-up survival data as of a 




Data from the 352 prospectively enrolled patients with a diagnosis of mRCC were analyzed 
for this report. Data collection began in 2011 and is ongoing. Patients receiving their last 
dose of HD IL-2 before January 1, 2015 were included in this analysis. All patients 
identified as meeting the following criteria were included in the prospective cohort analysis: 
18 years of age or older, diagnosed with mRCC, treated with at least 1 dose of HD IL-2, and 
with a posttreatment scan. All patients signed informed consent for data collection. 
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Enrolling sites agreed to enroll consecutive patients receiving at least 1 dose of HD IL-2. 
Available baseline data from enrolled patients included demographics (gender, age, and 
race) and clinical characteristics (Eastern Cooperative Oncology Group [ECOG] 
performance status, clear cell or non-clear cell histology, sites of metastasis, and prior 
treatment). Patients could have received multiple prior treatments which included, but were 
not limited to, surgery, chemotherapy, radiation, immunotherapy, TT, or other (Table 1). 
Patient eligibility at each site was confirmed by a study coordinator, and an Electronic Data 
Capture system was used to record the data. All data were subject to routine quality control 
procedures.
HD IL-2 Therapy
Physicians managed and treated patients with HD IL-2 (proleukin) per institutional standard 
of care and their own clinical judgment. HD IL-2 was generally administered intravenously 
at a dose of 600,000 IU/kg or 720,000 IU/kg over 15 minutes every 8 hours up to 14 
consecutive doses over 5 days (1 cycle of therapy). The majority of patients received a 
second cycle of HD IL-2 after approximately a 9-day rest period, per the discretion of the 
investigator. Two cycles of HD IL-2 treatment constituted 1 standard course of HD IL-2 
therapy. Additional courses were administered per the discretion of the treating physician. 
Sites were asked to enter the top 3 most affected organ systems during cycle dosing that lead 
to cycle conclusion, which included cardiac, renal, neurologic, metabolic, gastrointestinal, 
pulmonary, hematologic, vascular, hepatic, and cutaneous.
Study Design and Treatment
Patients were separated into groups based on when, if any, TT was administered (See 
Supplemental Figure 1 in the online version): patients who received no TT before or after 
HD IL-2 (“No TT” group), patients who received TT before HD IL-2 and could also have 
received TT after HD IL-2 (“Prior TT” group), and patients who received TT after HD IL-2 
and did not receive prior TT (“Post TT Only” group). In the “Prior TT” group there were 27 
patients who also received TT after HD IL-2 treatment. Specific TT agent data was 
collected, but not response to prior or post TT.
Toxicity data collection for the registry was designed to identify the reasons for holding 
doses or stopping treatment with IL-2. Therefore, investigators were asked to list the 3 organ 
systems affected that led to holding or stopping IL-2. These toxicities were not graded as per 
the common toxicity criteria, as these are inherent and expected in the management of 
patients receiving HD IL-2.
Response Evaluation to HD IL-2
The investigator, using either the World Health Organization criteria or Response Evaluation 
Criteria in Solid Tumors, depending on the individual physician preference and site 
standards, determined response to HD IL-2. Response was documented after each HD IL-2 
treatment course (2 cycles). Information on follow-up treatments after HD IL-2 therapy was 
collected approximately every 6 months after completion of HD IL-2 dosing until the final 
cutoff date for this analysis (September 24, 2015) or until patient death (whichever occurred 
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first). ORR was calculated as the summation of patients with complete response (CR) and 
partial response (PR) divided by all patients of the given group.
Statistical Analyses
All statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, 
NC). Patient characteristics, tumor response, and survival status were determined using data 
as of September 24, 2015. Frequency counts and measures of central tendency were 
performed to provide descriptive statistics. Kaplan-Meier curves with 95% confidence 
intervals (CIs) were used to estimate mOS (the primary outcome), with the log-rank test to 
determine significance (P < .05). Overall survival time was calculated from the date of the 
first dose of HD IL-2 to the date of death or the date of the most recent follow-up. One-, 2-, 
and 3-year survival probabilities were obtained using the Kaplan-Meier product limit 
method, and corresponding CIs were obtained using the Greenwood formula. Patients were 
followed until the date of death or until the last day of follow-up.
Results
Baseline Characteristics on HD IL-2 Therapy
Patient characteristics and demographics are listed in Table 1. The median age was 57 years 
(range, 25–83 years), but 20% of patients were 65 years of age or older. The majority of 
patients had an ECOG performance status (PS) of 0 (n = 237; 70%), whereas 97 (29%) 
patients had an ECOG PS of 1. Ninety-three percent of patients had clear cell histology and 
had a nephrectomy prior to HD IL-2 therapy. Non-clear cell histology was not further 
characterized in the registry and reflects only 23 patients (Table 1). Data on sites of and 
numbers of metastases was collected (Table 1) (See Supplemental Table 1 in the online 
version).
Response Data
Of 352 patients who were treated with HD IL-2, tumor response data was available for 328 
(93%) patients. There were 57 (17%) objective responses, which included 14 (4%) CRs and 
43 (13%) PRs. There were 129 (39%) additional patients who experienced stable disease 
(SD), and 142 (43%) had progressive disease (PD). In patients with CR (71%), PR (86%), or 
SD (88%), the majority of responses were determined after course 2 of therapy, whereas PD 
was diagnosed in 79% of patients after course 1 (See Supplemental Table 2 in the online 
version).
HD IL-2 Treatment
The number of IL-2 doses received in the Prior TT group compared with the No Prior TT 
group was similar for both groups. In the Prior TT group, the median number of doses 
received in cycle 1 and 2 was 9 and 8, respectively. For patients that did not receive prior TT, 
the median number of doses received was 9 and 7 for cycles 1 and 2, respectively.
The duration of HD IL-2 drug administration was assessed from the start of the first dose of 
HD IL-2 to the end of the last dose of HD IL-2, and included rest periods in between cycles 
and courses. For patients still alive at the time of analysis (n = 236), the median duration of 
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HD IL-2 drug administration was 2.5 months (range, 0.10–18.3 months) (See Supplemental 
Table 3 in the online version). For all patients (n = 352), the median duration of HD IL-2 
drug administration was 0.90 months (range, 0.03–18.3 months).
Survival Data
Survival estimates were calculated from the date of first dose of HD IL-2. The mOS was not 
reached for all patients based on the median follow-up of 21 months (Figure 1A). The 1-, 2-, 
and 3-year survival rates were 78%, 61%, and 52%, respectively. The mOS was not reached 
for patients who experienced CR (n = 14), PR (n = 43), or SD (n = 129), whereas patients 
who progressed (n = 142) had an mOS of 15.5 months (95% CI, 12.2–24.5 months). There 
was a statistically significant relationship between tumor response including SD and survival 
(P < .0001) (Figure 1B). The 2.5-year survival rate for patients with CR, PR, SD, and PD 
was 100%, 75%, 78%, and 39%, respectively.
Survival by Heng Criteria
To determine overall survival based on externally validated prognostic risk factors for 
mRCC, patients were separated into risk groups using the International mRCC Database 
Consortium model, also known as the Heng criteria.18 A series of 6 clinical factors were 
used to stratify patients into 3 prognostic groups. Patients were stratified into favorable (no 
factors), intermediate (1–2 factors), and poor (more than 3 factors) risk groups (Figure 2). 
These factors include: ECOG PS greater than or equal to 2, duration of less than 1 year from 
initial diagnosis to treatment, hemoglobin less than the lower limit of normal, serum-
corrected calcium greater than the upper limit of normal (ULN), absolute neutrophil count 
greater than ULN, and platelets greater than ULN.18 There were 271 patients (77%) who 
had complete data for all 6 parameters, of whom 50 patients (18%) stratified into the 
favorable-risk group, 196 patients (72%) into the intermediate-risk group, and 25 patients 
(9%) into the poor-risk group (Figure 2). The mOS for patients in the favorable-risk group 
was not reached, whereas the mOS for patients in the intermediate- and poor-risk groups 
was 35.5 (95% CI, 22.7-not estimable [NE]) and 12.6 (95% CI, 5.3–14.1) months, 
respectively.
Prior TT
There were 61 patients in the database who received TT prior to HD IL-2 treatment (Table 
2), referred to as the “Prior TT” group. Fifty-one patients (84%) received TT as their last 
treatment before starting HD IL-2. Forty-one patients (67%) had only 1 TT, and 20 patients 
(33%) had 2 or more TTs prior to HD IL-2. The most commonly prescribed TT was 
sunitinib, followed by pazopanib. In the Prior TT group, 55 (90.16%) of patients had clear 
cell histology. Sites of metastases are described in Supplemental Table 1 (in the online 
version). To determine whether patients with prior TT exposure benefited from HD IL-2 
therapy, response to HD IL-2 was assessed. Data were available for 53 (87%) of the 61 Prior 
TT patients. The ORR in this set of patients was 19%. One patient achieved CR, and 9 
patients achieved a PR at final tumor assessment after completing HD IL-2 therapy. Fourteen 
patients (26%) achieved SD, and 29 patients (55%) experienced PD as their final tumor 
response to HD IL-2. The mOS across all Prior TT patients, calculated from the time of HD 
IL-2 treatment, was 22.1 months (95% CI, 13.08- NE) (Figure 3A). The mOS was not 
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reached in patients attaining CR, PR, or SD, and there was no statistically significant 
differences in mOS across these 3 subgroups (Figure 3B). There was statistical significance 
in comparing each of the aforementioned groups with the mOS of PD patients, which was 
13.1 months (95% CI, 7.7–16.6 months). The 2.5-year survival rate for CR, PR, SD, and PD 
was 100%, 100%, 68%, and 20%, respectively (Figure 3B). Among the 61 patients in the 
Prior TT group, 27 patients received subsequent treatment with TT after HD IL-2.
IL-2 Only (No TT) and Post-IL-2 TT Groups
There were 142 patients in the database who received no TT before or after HD IL-2 
treatment, referred to here as the “No TT” group. There were 149 patients who received TT 
after completing HD IL-2 therapy and did not receive prior TT, referred to here as the “Post 
TT Only” group. The number of metastases and sites of metastases are described in 
Supplemental Table 1 (in the online version). The mOS for the No TT group was not 
reached (95% CI, NE-NE), and for the Post TT only group was 35.5 months (95% CI, 24.4-
NE) (Figure 4A). There was no statistically significant difference in mOS between the Post 
TT Only group and the No TT group (P > .05). Survival estimates were stratified by tumor 
response to HD IL-2 for both groups (Figures 4B and 4C). Response data was available for 
143 (96%) patients in the Post TT Only group and 132 (93%) patients in the No TT group. 
For patients in the Post TT Only group, the mOS for patients with CR (n = 3), PR (n = 9), or 
SD (n = 50) was not reached, whereas the mOS for patients with PD (n = 81) was 29.7 
months (95% CI, 17.0-NE) (Figure 4B). The 2.5-year survival rate for patients with CR, PR, 
SD, and PD was 100%, 55%, 68%, and 51%, respectively. For the No TT group, the mOS 
for patients with CR (n = 10), PR (n = 25), or SD (n = 65) was not reached, whereas the 
mOS for patients with PD (n = 32) was 8.5 months (95% CI, 5.6–12.6 months) (Figure 4C). 
The 2.5-year survival rate for patients attaining CR, PR, SD, and PD was 100%, 79%, 92%, 
and 20%, respectively.
Safety
There were 5 reported deaths related to HD IL-2 drug administration in 352 patients, 
translating to a drug-related death rate of 1.4%. One patient with a history of hypertension 
and hypercholesterolemia discontinued cycle dosing because of acute kidney injury and 
hypotension, and eventually expired owing to ischemic bowel. One patient who experienced 
hypotension and shortness of breath experienced progressive renal failure prior to death. 
Another patient required intubation after stopping cycle dosing for anion gap acidosis and 
worsening hypotension, became asystolic, and died. A single patient with metastases to the 
lung and brain experienced expected HD IL-2-related toxicity that resolved with medical 
management during cycle 1; however, following 11 of 14 doses during cycle 2, this patient 
experienced bradycardia, became unresponsive, and died. Only 1 of the 5 patients that 
expired because of toxicities related to IL-2 drug treatment had received prior TT, and that 
agent was bevacizumab. This patient received 11 doses of HD IL-2 during cycle 1. The 
cause of death was attributed to respiratory failure with increased pulmonary infiltrates.
For cycle 1 dosing, in both the Prior TT and No TT groups, the top 3 most affected organ 
systems were cardiac, renal, and neurologic. The most common reported cardiac toxicities 
were hypotension followed by arrhythmia for both groups. There were no differences in 
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rates or expected toxicities for HD IL-2 between groups. Specifically there were no 
unexpected cardiac toxicities noted for the Prior TT group. A summary of toxicities by 
organ system leading to holding or stopping HD IL-2 for the first 4 cycles of HD IL-2 is 
described in Supplemental Table 4 (in the online version). Of note, these are all expected 
toxicities and characteristic of HD IL-2 treatment.
Discussion
TTs are the most commonly used first-line therapy for mRCC, yet HD IL-2 remains the only 
agent that has shown durable responses in selected patients. The optimal sequencing of these 
agents towards maximizing benefit remains uncertain. HD IL-2 has significant clinical 
benefit and should be considered an option for selected patients with appropriate 
performance status. In this analysis, patients who progressed on or after TT and were 
eligible for HD IL-2 had an objective response rate of 19% with no unexpected toxicities 
noted.
Another key observation that emerged from this analysis in PROCLAIMSM was that patients 
who did not receive targeted therapies before HD IL-2 or require TT soon after HD IL-2 
treatment experienced prolonged clinical benefit (Figure 1B), again confirming durable 
benefit from HD IL-2 based on this “real world” data. This finding was also noted most 
recently in the IL-2 “select” trial, and was demonstrated in long-term follow-up reports of 
patients receiving IL-2 therapy.12,13,16
A third important finding from this analysis of PROCLAIMSM is that patients with SD 
experienced similar survival outcomes as did patients with PRs, and that this translates into 
meaningful clinical benefit (Figures 1B, 3B, 4B, 4C). This was observed in the overall group 
as well as in the subgroups related to timing of TT. As shown in Figure 1B, overall, 129 
patients achieved SD, and the mOS for these patients was not reached. For patients with 
prior TT, 14 (26%) achieved SD, and likewise, the mOS was not reached (Figure 3B). Until 
recently, SD had not been considered a relevant statistical endpoint, but recent appreciation 
and understanding of the mechanism of action of TTs and newer immunotherapies is 
shifting this view. Given the delayed kinetics necessary to mediate immune-based tumor 
rejection, patients with SD may be able to achieve long-term survival benefit, making 
objective response rates an incomplete and/or insufficient assessment of clinical benefit in 
response to immunotherapy agents.
Several single-institution reports are consistent with these prospectively collected multi-
center “real world” data from the PROCLAIMSM registry. A recent retrospective report by 
Lam et al showed an ORR of 13% in patients treated with HD IL-2 following an anti-VEGF 
tyrosine kinase inhibitor (TKI), including CRs.19 The authors concluded that administration 
of HD IL-2 could be safe and effective following TKI therapy, and recommended a TKI to 
HD IL-2 interval of at least 2 months.19 The efficacy of HD IL-2 in patients with prior 
VEGF TTs was also reported by Evans et al.20 In this report, 23% of VEGF treatment-naive 
patients achieved complete responses compared with 19% among patients pretreated with 
anti-VEGF agents. Both groups consisted of approximately 88% with “favorable” histology. 
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In these analyses, mOS was not reached in patients attaining CR, PR, or SD with HD IL-2, 
demonstrating that HD IL-2 was active in patients who have received prior TTs.
Additionally, a recent publication from Roswell Park by Hanzly et al reported that the mOS 
for patients initially treated with TT and followed by HD IL-2 was 5 months compared with 
an mOS of 40 months for patients treated initially with HD IL-2 and then TT. There were no 
treatment-related deaths in this report.14 Because this was a retrospective observational 
report as well, it is uncertain whether these differences are because of patient selection, lead-
time bias of pretreated patients, or to follow-on treatment of other therapies. Nevertheless, 
clinical benefit was observed with institution of subsequent TT in patients experiencing PD 
after HD IL-2, resulting in an mOS of 29.7 months compared with 8.6 months in patients 
who did not receive TT.
These observations suggest that access to newer TTs may be one reason for enhanced 
survival benefit among patients with RCC treated initially with HD IL-2. Birkhauser et al 
from UCLA have reported similar results, with a median disease-specific survival of 83 
months in 51 patients who received TT after progressing on HD IL-2, versus 30 months in 
233 patients treated in the same institution with TT alone.21
Addressing the possibility of pre-selection as a basis for survival improvement in 
contemporary HD IL-2 treatment reports, we applied the International Metastatic RCC 
Database Consortium prognostic model (Heng criteria) for mRCC.18 When applied to the 
PROCLAIMSM registry, a large majority of patients who received HD IL-2 were found to 
stratify into the intermediate-prognosis group (72%) and not the favorable-risk group (18%). 
This suggests that the observed improved OS is less likely attributable to a favorable risk 
group pre-selection bias.
For patients with mRCC, 2006 marked the beginning of availability of TT options such as 
sorafenib, sunitinib, bevacizumab, pazopanib, axitinib, everolimus, temsirolimus, 
cabozantinib, nivolumab, and the combination of lenvatinib with everolimus that has 
resulted in a shift away from HD IL-2 use.11 The ability to apply these agents to greater 
numbers of patients with mRCC might in part explain the improved overall survival in the 
modern era of HD IL-2 therapy, compared with historical experience. Better patient 
screening and improved patient management may also be factors. The ability to receive HD 
IL-2 early in the course of mRCC may delay the need for subsequent therapy, and with the 
durable SD noted in this study, add time off-treatment for these patients.
The recent introduction of T cell checkpoint blockade with antibodies directed against the 
programmed cell death receptor-1 (nivolumab and pembrolizumab),22,23 is also changing the 
treatment landscape for a range of solid tumors, including mRCC.9,24,25 As newer TTs and 
immune therapies continue to be introduced, it will be critical to understand the safety and 
efficacy of these agents when used serially or concomitantly. PROCLAIMSM represents the 
largest collection of clinical data involving HD IL-2-treated patients in the US, and is useful 
in hypothesis generation regarding the safety and efficacy of serially applied or combined 
therapies as it relates to HD IL-2.
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Data extracted from clinical registries are susceptible to uncontrolled sources of bias (eg, 
differences in cancer treatments across groups being compared). Clinicians could apply 
variable methodologies to determine progression on the basis of clinical and radiographic 
data; for example, response to HD IL-2 was determined by the investigator using either the 
World Health Organization criteria or Response Evaluation Criteria in Solid Tumors, 
depending on the individual physician preference and site standards. Although 
PROCLAIMSM investigators were asked to enter consecutive patients into the registry, the 
actual inclusion of patients occurred at the investigators’ discretion and patients’ willingness 
to consent to study participation. Data from this registry is not representative of all patients 
with mRCC, owing to differences in eligibility criteria for HD IL-2 therapy across centers.
Conclusions
Data from this observational clinical trial (PROCLAIMSM) provide real-world clinical data 
on safety and efficacy of sequential TTs used with HD IL-2 for patients with mRCC. The 
data presented here suggest that HD IL-2 should be considered as an initial option before TT 
in eligible patients. Additionally, we report that HD IL-2 can be safe and effective in patients 
who were pretreated with anti-VEGF TTs. The survival benefit appears to extend to patients 
achieving SD, and is quite durable. The current treatment-related death rate is lower than 
historical experience and is likely owing to improved treatment practices and better patient 
selection criteria.
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• HD IL-2 is an immunotherapy with curative potential for mRCC.
• There are few clinical studies performed to assess the potential benefits of 
sequencing HD IL-2 with TT.
• PROCLAIMSM registry data suggest that the highest survivals were attained by 
patients who received initial HD IL-2 followed by subsequent TT. HD IL-2 
should hence be considered a first-line therapy option in eligible patients.
• HD IL-2 can be active and administered safely in patients who have failed 
prior treatments with TT and still meet HD IL-2 eligibility criteria.
• HD IL-2 has an acceptable efficacy and safety profile in the current clinical 
practice and remains a valuable therapy for eligible patients with mRCC.
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Overall Survival. A, Analysis Population, n [ 352. Data Was Available for All 352 Patients; 
of These, 116 Were Confirmed Deceased and 236 Were Known to Be Alive at the Last 
Follow-up Date of September 24, 2015. The Overall Survival Data (Not Reached [NR]) Was 
Calculated From the Time of Starting High-dose Interleukin-2 (HD IL-2) Therapy. The 
Median Follow-up Was 21 Months. Vertical Bars Represent Censored Subjects. B, Overall 
Survival by Response to HD IL-2. Response Rate Was Available for 328 of 352 Patients. 
The Median Overall Survival (mOS) for Patients With Complete Response (CR), Partial 
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Response (PR), and Stable Disease (SD) Was Not Reached. One Hundred Forty-Two 
Patients With Progressive Disease (PD) After HD IL-2 Experienced an mOS of 15.5 
Months. Vertical Bars Represent Censored Subjects
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Kaplan-Meier Overall Survival by the International mRCC Database Consortium Risk 
Factors. Six Risk Factors Were Considered Using the International mRCC Database 
Consortium Prognostic Model. Patients Were Grouped Into 3 Categories: Favorable [ 0, 
Intermediate [ 1–2, Poor [ 3 D Risk Factors. Two Hundred Seventy-One Patients had 
Complete Data for All 6 Prognostic Factors and Were Included in the Analysis. Fifty 
Patients Were in the Favorable Group, 196 Were in the Intermediate Group, and 25 Were in 
the Poor Group. Vertical Bars Represent Censored Subjects
Abbreviations: mOS = median overall survival; mRCC = metastatic renal cell carcinoma; 
NR = not reached.
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Kaplan-Meier Overall Survival of Patients Receiving Prior Targeted Therapy (TT). A, 
Overall Survival of All Patients in the Prior TT Group. B, Overall Survival of Patients in the 
Prior TT Group by Response to High-dose Interleukin-2 (HD IL-2). Vertical Bars Represent 
Censored Subjects
Abbreviations: CR = complete response; mOS = median overall survival; NR = not reached; 
PD = progressive disease; PR = partial response; SD = stable disease.
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Kaplan-Meier Overall Survival in Patients With HD IL-2 Alone or Post-targeted Therapy 
(TT). A, Overall Survival of Patients in the Post TT Only Group Compared With No TT 
Group (P = .88). B, Overall Survival of Patients in the Post TT Only Group by Response to 
High-dose Interleukin-2 (HD IL-2). Vertical Bars Represent Censored Subjects. C, Overall 
Survival of Patients in the No TT Group by Response to HD IL-2. Vertical Bars Represent 
Censored Subjects
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Abbreviations: CR = complete response; mOS = median overall survival; NR = not reached; 
PD = progressive disease; PR = partial response; SD = stable disease.
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 Female 96 27
 Male 256 73
Age, y
 <65 281 80
 ≥65 71 20
 Median 57 NA











 Missing 13 4
Race
 White 326 93
 Black 8 2
 Asian 4 1
 Other 8 2
 Decline 6 2
Clear cell
 No 23  7
 Yes 329 93
Prior nephrectomy
 No 24  7
 Yes 328 93
Total/partial
a
 Partial 33 10
 Total 295 90
Prior treatments
 Surgery 331 94
 Chemotherapy 10 3
 Radiation 55 16
 Immunotherapy 6 2
 Targeted therapy 61 17
 Other 13 4
Metastases
 Skin, lungs, LNs only 165
48
a
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Characteristics N %




 Missing 7 2
Abbreviations: ECOG PS = Eastern Cooperative Oncology Group performance status; HD IL-2 = high-dose interleukin-2; LN = lymph node.
a
Does not include missing data in the denominator.
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Table 2
Prior TT
Total (N = 61)
Patients with Prior TT N %
Last treatment before starting HD-IL2
  TT 51 84
  Radiation   5   8
  Immunotherapy   2   3
  Other   3   5
No. of prior targeted therapies
  Only 1 prior TT 41 67
  Only 2 prior TTs   4   7
  Only 3–5 prior TTs 16 26
TTs used
a
  Sunitinib 39 38
  Pazopanib 19 18
  Everolimus 12 12
  Temsirolimus 11 11
  Axitinib 10 10
  Sorafenib   6   6
  Bevacizumab   4   4
  Other   3   3
Classification of TTs
  TKI only 37 61
  mTOR only   6 10
  VEGF only   1   2
  mTOR and TKI 13 21
  VEGF and TKI   1   2
  TKI, VEGF, and mTOR   3   5
Abbreviations: HD IL-1 = high-dose interleukin-2; mTOR = mammalian target of rapamycin; TKI = tyrosine kinase inhibitors; TT = targeted 
therapy; VEGF = vascular endothelial growth factor.
a
Based on patients with available data.
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